62 results
8-K
EX-99.1
CHRS
Coherus Biosciences Inc
13 Mar 24
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
4:16pm
share
In the year ended December 31, 2023, stock-based compensation of $1.0 million was classified within Restructuring charges related to reduction
8-K
EX-2.1
CHRS
Coherus Biosciences Inc
22 Jan 24
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in Conference Call Information
8:01am
”) without fully satisfying its obligations under WARN.
(f) Seller and its Subsidiaries have, in all material respects, correctly classified all Company
8-K
EX-99.1
m7h88ds
6 Nov 23
Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights
4:31pm
8-K/A
EX-99.1
p2yhvn1
6 Nov 23
Report of Independent Registered Public Accounting Firm
6:07am
8-K
EX-99.1
onzq6nne cve01a6
2 Aug 23
Coherus BioSciences Reports Second Quarter 2023 Financial Results and Business Highlights
4:05pm
425
jib2willj
16 Jun 23
Business combination disclosure
8:08am
425
f18axlc7vqcgg
16 Jun 23
Business combination disclosure
7:09am
8-K
EX-2.1
rfxqomhpogn36s
16 Jun 23
Coherus to Acquire Surface Oncology
7:06am
8-K
EX-99.1
9wc7 7xcfhqisdrtsd
8 May 23
Coherus BioSciences Reports First Quarter 2023 Financial Results and Business Highlights
4:16pm